- PackSize
- 50ug/100ug
- Target
- CD178
- Reactivity
- Human
- Applications
- ELISA, Functional assay, Research in vivo
- Host Species
- Mammalian Cells
- Isotype
- Fusion - [FAS (Fas cell surface death receptor, TNFRSF6, tumor necrosis factor receptor (TNFR) superfamily member 6, FAS1, APO-1, CD95)]2 - IGHG1 Fc (Fragment constant)
- Conjugate/Modification
- --
- Recommended Dilution Ratio
- --
- Composition
- 0.01M PBS, pH 7.4.
- Purification Process
- Protein A/G purified from cell culture supernatant.
- Purity
- >95% purity as determined by SDS-PAGE.
- storageCondition
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
- Clonality
- --
- Clone Number
- --
- Immunogen
- Mammalian Cells
- Alias
- Receptor-binding FasL ectodomain, APL, APT1LG1, FasL ICD, Fas antigen ligand, CD178, sFasL, CD95L, APTL, TNFSF6, Apoptosis antigen ligand, SPA, FASLG, FasL, SPPL2A-processed FasL form, Tumor necrosis factor ligand superfamily member 6, Soluble Fas ligand, Fas ligand, CD95 ligand, CD95-L, FASL
- Species
- --
- Gene ID-1
- P48023
- Uniprot
- --
- Background
- Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD).<br>
- Tissue Expression
- --
- Signaling_pathway
- --
- Research Areas
- --